Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Fiche publication
Date publication
novembre 2021
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, van der Woude CJ, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L
Lien Pubmed
Résumé
Crohn's disease (CD) patients included in the TAILORIX trial started infliximab in combination with an immunosuppressant for one year. The aim of the present study was to determine the long-term disease course beyond the study period.
Mots clés
Crohn’s disease, deep remission, endoscopic remission, infliximab
Référence
Clin Gastroenterol Hepatol. 2021 Nov 26;: